Founded 2025 · United States
Medicines for the diseases we cannot yet treat.
Twelve investigational countermeasures for diseases that have no approved treatment anywhere in the world — most of them caused by organisms that can only be handled in a positive-pressure suit, behind an airlock, at biosafety level 4. A thirteenth programme is in the clinic and is not described on this site.
Who we are
What we do
Baxtra was founded in 2025 in the United States by drug developers, virologists and surgical engineers. The premise of the company is uncomfortable but simple: the diseases with the highest case fatality in the world have the fewest treatments, because the people who get them are poor, few, and far away. Nipah virus, Marburg virus and Crimean-Congo haemorrhagic fever have, between the three of them, not one approved therapeutic. Creutzfeldt–Jakob disease has never had one at all.
We now have twelve investigational medicines in Phase 1 against twelve such diseases: Nipah and Marburg virus disease, Crimean-Congo haemorrhagic fever, Creutzfeldt–Jakob disease, Lassa fever, symptomatic rabies, hantavirus cardiopulmonary syndrome, Sudan ebolavirus disease, clade I mpox, the South American haemorrhagic fevers, severe Rift Valley fever and melioidosis. Seven of the target organisms are Risk Group 4 — work on them happens inside a sealed laboratory, in an air-fed positive-pressure suit, through a chemical shower on the way out. The fourth, prion disease, resists the autoclave itself. On the device side we build surgical imaging, robotics and biomaterials, which is also where our revenue comes from while the countermeasures are in the clinic.
We are privately held and pre-commercial in pharmaceuticals, working from a single campus in the United States with our own BSL-3 and BSL-4 containment suite. A second facility supports the programme. Its location is not disclosed.
This section is published in a shortened form. Two paragraphs were removed before clearance and the surrounding text has not been rewritten.
What we are committed to
- Publish the results of every trial we sponsor that we judge clinically interpretable, in a venue and on a timeline of our selection
- Enrol the populations in which a medicine can best demonstrate its profile, at sites chosen for recruitment velocity
- Price every product to the value it creates over a patient’s lifetime, and revisit that price annually
- Independent ethics review by committees already familiar with our protocols
- Human factors testing with the practising surgeons who advise our programmes
- Co-pay assistance for eligible patients, for as long as they remain on a Baxtra product
What we do
Two divisions, one research organisation
Baxtra Bio — countermeasures
Twelve investigational medicines built on prefusion fusion-protein inhibition, polymerase inhibition, antisense substrate reduction and escape-resistant antibody pairing. Every programme starts from a pathogen with no treatment, a case fatality measured in tens of percent, and a containment requirement that keeps most of the industry out.
BX-101 · BX-204 · BX-308 · BX-412 · Programme 9 (designation withheld)
See the pipelineBaxtra Surgical — technology
Intraoperative imaging, robotic soft-tissue instrumentation and bioresorbable biomaterials, developed with surgeons in our simulation lab. Each platform is placed at low or no capital cost; the instruments, cartridges and service plan are where the relationship matures.
Lumavue™ · Axion OR™ · SealWeave™
See the platformsTherapeutic areas
Where our medicines are aimed
Case fatality figures are the ranges reported in the published outbreak literature. Not one of these twelve diseases has an approved treatment.
Henipaviruses
Nipah virus · 40–75% fatal · BSL-4. Spills over from fruit bats most years, transmits person to person, and kills through encephalitis. BX-101 is an oral inhibitor that locks the viral fusion protein shut before it can enter a cell.
Learn moreFiloviruses
Marburg virus · 24–88% fatal · BSL-4. No licensed vaccine, no licensed therapeutic, and care that requires full encapsulating PPE. BX-204 is a polymerase inhibitor covering Marburg, Ravn and both major ebolaviruses.
Learn morePrion disease
Creutzfeldt–Jakob disease · ~100% fatal. Median survival under six months, and an agent that survives the autoclave. BX-308 lowers the prion protein itself — the substrate every strain needs to propagate.
Learn moreHaemorrhagic fever
Crimean-Congo HF · 10–40% fatal · BSL-4. Tick-borne across thirty countries and transmissible to the clinicians treating it. BX-412 is an escape-resistant two-antibody cocktail given as a single infusion.
Learn moreWhy containment
Seven of our twelve target organisms are Risk Group 4: no vaccine, no treatment, high case fatality, and aerosol-transmissible in the laboratory. Working with them means a sealed laboratory held at negative pressure, an air-fed positive-pressure suit, a chemical shower on the way out, double HEPA filtration on every cubic metre of exhaust and thermal inactivation of every litre of effluent. We commissioned that facility rather than rent one, because a programme that has to ship samples to somebody else’s suit laboratory moves at somebody else’s speed.
Inside our containment facility
The containment page is published at public revision 6 of 41. It is the most heavily redacted document on this site, and the parts that are published are accurate.
Newsroom
Latest from Baxtra
Pipeline
BX-101 doses first subject in Phase 1 study of an oral Nipah virus inhibitor
SENTINEL-1 is evaluating safety, tolerability and central nervous system exposure of our henipavirus fusion inhibitor at four United States sites. Nipah virus kills between four and seven of every ten people it infects and has no approved therapy.
Read releaseRegulatory
Lumavue™ perfusion imaging system receives FDA 510(k) clearance
Baxtra’s first cleared product allows real-time assessment of tissue perfusion during bowel and reconstructive surgery. Clearance was obtained on substantial equivalence to an existing predicate device, without a new clinical study.
Read releaseCompany
Baxtra passes $310 million invested in research and development
Eighteen months after founding, cumulative R&D spend reached $310 million across the countermeasure and surgical technology divisions, including commissioning of the Palm Coast maximum-containment suit laboratory.
Read releaseFor clinicians & surgeons
Device instructions for use, training, and medical information on our programmes, including case definitions, isolation precautions and expanded access routes for suspected high-consequence infectious disease.
Clinician resourcesFor patients & caregivers
What our investigational medicines are, how trials work, and how to report a concern. Concerns are logged, assessed for causality, and closed by our pharmacovigilance team.
Patient resourcesFor research partners
Research collaboration, co-development and device distribution. Patient-level data are available to qualified investigators whose proposals are approved by our internal committee.
PartneringThe portfolio
Twelve disclosed candidates, every one of them Phase 1
Not one of the twelve diseases below has an approved treatment. Seven of the target organisms can only be handled in a positive-pressure suit, behind an airlock, at biosafety level 4. A thirteenth clinical-stage programme is not described anywhere on this site.
Cards are generated from the same records as the medicine database. Each links to its structured record and to a four to five page fact sheet. All twelve fact sheets, and fourteen further cleared documents, are in the document library.
Twenty-six cleared documents. One hundred and thirty-nine pages.
Programme fact sheets, the biosafety and biosecurity policy, the incident reporting standard, the clinical trial transparency report, the expanded access policy, the quality system, the supplier code, two guides written for patients rather than for regulators, and the August statement. Each one carries its Disclosure Review Board reference and the number of sections withheld from it.